Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Akebia Therapeutics (AKBA) Operating Margin (2017 - 2025)

Akebia Therapeutics (AKBA) has disclosed Operating Margin for 9 consecutive years, with 14.84% as the latest value for Q4 2025.

  • Quarterly Operating Margin rose 1593.0% to 14.84% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 9.95% through Dec 2025, up 4146.0% year-over-year, with the annual reading at 9.95% for FY2025, 4146.0% up from the prior year.
  • Operating Margin for Q4 2025 was 14.84% at Akebia Therapeutics, down from 7.57% in the prior quarter.
  • The five-year high for Operating Margin was 8648.48% in Q2 2022, with the low at 5444.92% in Q4 2021.
  • Average Operating Margin over 5 years is 116.07%, with a median of 33.41% recorded in 2024.
  • The sharpest move saw Operating Margin surged 879842bps in 2022, then tumbled -866443bps in 2023.
  • Over 5 years, Operating Margin stood at 5444.92% in 2021, then skyrocketed by 97bps to 162.3% in 2022, then soared by 81bps to 31.0% in 2023, then increased by 1bps to 30.77% in 2024, then soared by 52bps to 14.84% in 2025.
  • According to Business Quant data, Operating Margin over the past three periods came in at 14.84%, 7.57%, and 22.55% for Q4 2025, Q3 2025, and Q2 2025 respectively.